In utero exposure to breast cancer treatment: a population-based perinatal outcome study

Br J Cancer. 2019 Oct;121(8):719-721. doi: 10.1038/s41416-019-0563-x. Epub 2019 Sep 6.

Abstract

Chemotherapy during a viable pregnancy may be associated with adverse perinatal outcomes. We conducted a prospective cohort study to examine the perinatal outcomes of babies born following in utero exposure to chemotherapy in Australia and New Zealand. Over 18 months we identified 24 births, of >400 g and/or >20-weeks' gestation, to women diagnosed with breast cancer in the first or second trimesters. Eighteen babies were exposed in utero to chemotherapy. Chemotherapy commenced at a median of 20 weeks gestation, for a mean duration of 10 weeks. Twelve exposed infants were born preterm with 11 by induced labour or pre-labour caesarean section. There were no perinatal deaths or congenital malformations. Our findings show that breast cancer diagnosed during mid-pregnancy is often treated with chemotherapy. Other than induced preterm births, there were no serious adverse perinatal outcomes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Australia / epidemiology
  • Breast Neoplasms / drug therapy*
  • Carboplatin / administration & dosage
  • Case-Control Studies
  • Cesarean Section
  • Cohort Studies
  • Congenital Abnormalities / epidemiology*
  • Continuous Positive Airway Pressure
  • Cyclophosphamide / administration & dosage
  • Docetaxel / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Gestational Age
  • Humans
  • Infant, Low Birth Weight
  • Infant, Newborn
  • Infant, Small for Gestational Age
  • Labor, Induced
  • New Zealand / epidemiology
  • Paclitaxel / administration & dosage
  • Perinatal Death*
  • Pregnancy
  • Pregnancy Complications, Neoplastic / drug therapy*
  • Pregnancy Trimester, First
  • Pregnancy Trimester, Second
  • Premature Birth / epidemiology*
  • Prospective Studies
  • Respiratory Distress Syndrome, Newborn / epidemiology
  • Respiratory Distress Syndrome, Newborn / therapy
  • Stillbirth / epidemiology*
  • Tamoxifen / administration & dosage
  • Trastuzumab / administration & dosage

Substances

  • Tamoxifen
  • Docetaxel
  • Doxorubicin
  • Cyclophosphamide
  • Carboplatin
  • Trastuzumab
  • Paclitaxel